APACMed：2025年赋能决策：真实世界证据在亚太地区医疗器械支付决策中的应用与未来报告（英文版）

Despite the rapid growth of the medical technology industry in recent years, health technology assessment (HTA) for medical technologies remains less developed and less robust compared to pharmaceuticals. Due to inherent dierences between medical technologies and pharmaceuticals which influence HTA methodologies, there is great value in utilising real-world data (RWD) and real-world evidence (RWE) to support payer decision-making for medical technologies. However, adoption of RWE continues t